Why Illumina's Stock Is Trading Lower Today

Illumina ILMN shares are trading lower on Monday following a report that the company will acquire privately-held life sciences firm Grail for $7.1 billion in cash and stock.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (73% of 2019 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening.

Illumina shares were trading down 8.4% at $270.66 on Monday during the time of publication. The stock has a 52-week high of $404.20 and a 52-week low of $196.78.

Loading...
Loading...
ILMN Logo
ILMNIllumina Inc
$90.250.87%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
17.08
Growth
21.26
Quality
6.24
Value
22.60
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...